Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azathioprine + prednisone
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination immunosuppressive therapy consisting of azathioprine and prednisone. Azathioprine is a prodrug of 6-mercaptopurine that inhibits purine synthesis, while prednisone is a corticosteroid with anti-inflammatory and immunosuppressive properties. This combination has shown superior efficacy compared to prednisone monotherapy in treating various inflammatory and autoimmune conditions, allowing for more frequent and quicker remission with lower corticosteroid doses.
- Other names
- AZAPRED
02
Targets
GR (Glucocorticoid receptor)DNAPPAT (Amidophosphoribosyltransferase)
Beyond the preview
Go deeper on azathioprine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azathioprine + prednisone.